Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease.
+40% in stock price, + more after hours. Potential price point of $100/share on early approval.
Submitted July 03, 2018 at 08:43PM by yellowhorseNOT https://ift.tt/2zjbrxV
